Evidence map›Paper›PMID 35084124›Full record

ArticleBrain and behavior2022

Changes in serum neurofilament light chain levels following narrowband ultraviolet B phototherapy in clinically isolated syndrome.

Marzena J Fabis-Pedrini, Jens Kuhle, Katherine M A Roberts, Stephanie Trend, Anderson P Jones, Aleksandra Maceski, William M Carroll, Robyn M Lucas, Frank L Mastaglia, Prue H Hart and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain and behavior, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Marzena J Fabis-PedriniPerron Institute for Neurological and Translational Science, University of Western Australia, Perth, Australia.ORCID 0000-0002-2614-8607
Jens KuhleNeurology Clinic and Policlinic, MS Centre and Research Centre for Clinical Neuroimmunology and Neuroscience Basel, University of Basel, Basel, Switzerland.
Katherine M A RobertsPerron Institute for Neurological and Translational Science, University of Western Australia, Perth, Australia.
Stephanie TrendPerron Institute for Neurological and Translational Science, University of Western Australia, Perth, Australia.
Anderson P JonesTelethon Kids Institute, University of Western Australia, Perth, Australia.
Aleksandra MaceskiNeurology Clinic and Policlinic, MS Centre and Research Centre for Clinical Neuroimmunology and Neuroscience Basel, University of Basel, Basel, Switzerland.
William M CarrollPerron Institute for Neurological and Translational Science, University of Western Australia, Perth, Australia.
Robyn M LucasNational Centre for Epidemiology & Population Health, Research School of Population Health, Australian National University, Canberra, Australia.
Frank L MastagliaPerron Institute for Neurological and Translational Science, University of Western Australia, Perth, Australia.
Prue H HartTelethon Kids Institute, University of Western Australia, Perth, Australia.
Allan G KermodePerron Institute for Neurological and Translational Science, University of Western Australia, Perth, Australia.
Murdoch University · AUThe Kids Research Institute Australia · AUThe University of Western Australia · AUUniversity of Basel · CHAustralian National University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine whether serum neurofilament light chain (sNfL) levels are suppressed in patients with the clinically isolated syndrome (CIS) following narrowband ultraviolet B phototherapy (UVB-PT).

methodssNfL levels were measured using a sensitive single-molecule array assay at baseline and up to 12 months in 17 patients with CIS, 10 of whom received UVB-PT, and were compared with healthy control (HC) and early relapsing remitting multiple sclerosis (RRMS) group. sNfL levels were correlated with magnetic resonance imaging total lesion volume (LV) determined using icobrain version 4.4.1 and with clinical outcomes.

resultsBaseline median sNfL levels were significantly higher in the CIS (20.6 pg/mL, interquartile range [IQR] 13.7-161.4) and RRMS groups (36.6 pg/ml [IQR] 16.2-212.2) than in HC (10.7 pg/ml [IQR] 4.9-21.5) (p = .012 and p = .0002, respectively), and were strongly correlated with T2 and T1 LV at 12 months (r = .800; p = .014 and r = .833; p = .008, respectively) in the CIS group. Analysis of changes in sNfL levels over time in the CIS group showed a significant cumulative suppressive effect of UVB-PT in the first 3 months (UVB-PT -10.6% vs non-UVB-PT +58.3%; p = .04) following which the levels in the two groups converged and continued to fall.

conclusionsOur findings provide the basis for further studies to determine the utility of sNfL levels as a marker of neuro-axonal damage in CIS and early MS and for assessing the efficacy of new therapeutic interventions such as UVB-PT.

Indexed as

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingAxonsBiomarkersHumansIntermediate FilamentsPhototherapyBiomarkersclinically isolated syndromelesion volumemultiple sclerosisneurofilament light chainultraviolet B

Identifiers

PMID35084124
PMCPMC8865160
OpenAlexW4210353583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.